SCHEMBL2239637

SCHEMBL2239637

COc1cc(NS(=O)(=O)c2ccc(NC3=C(C)C(=O)c4ccccc4C3=O)cc2)nc(OC)n1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 4/20 0.67
SMN1; SMN2 Q16637 2/20 0.61
KMT2A Q03164 7/20 0.61
ALDH1A1 P00352 2/20 0.61
HTT P42858 1/20 0.61
LMNA P02545 2/20 0.60
CYP3A4 P08684 1/20 0.60
HTR6 P50406 1/20 0.60
MEN1 O00255 3/20 0.59
KDM4E B2RXH2 1/20 0.59
MAPT P10636 1/20 0.59
GPR55 Q9Y2T6 1/20 0.59
GAA P10253 1/20 0.57
HSD17B10 Q99714 1/20 0.57
PPP1CA P62136 1/20 0.57
POLB P06746 2/20 0.55
NPSR1 Q6W5P4 1/20 0.55
ALOX12 P18054 1/20 0.55
P2RY1 P47900 1/20 0.55
RXFP1 Q9HBX9 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2240548 0.90 AKT1 (0.64) AKT1SMN1; SMN2KMT2AALDH1A1HTT
SCHEMBL7975646 0.86 AKT1 (0.60) AKT1SMN1; SMN2KMT2AALDH1A1HTT
SCHEMBL21753106 0.81 ALDH1A1 (0.76) AKT1SMN1; SMN2KMT2AALDH1A1HTT
SCHEMBL328335 0.80 AKT1 (1.00) AKT1SMN1; SMN2KMT2AALDH1A1HTT
SCHEMBL7824834 0.79 ALDH1A1 (0.78) AKT1SMN1; SMN2KMT2AALDH1A1HTT
SCHEMBL2239357 0.79 ALDH1A1 (0.74) SMN1; SMN2KMT2AALDH1A1LMNAMEN1
Sulfadimethoxine SCHEMBL29363944 0.76 LMNA (1.00) AKT1SMN1; SMN2KMT2AALDH1A1HTT
Sulfadimethoxine SCHEMBL93845 0.76 LMNA (1.00) AKT1SMN1; SMN2KMT2AALDH1A1HTT
SCHEMBL328334 0.75 ALOX12 (0.81) AKT1SMN1; SMN2KMT2AALDH1A1HTT
SCHEMBL2241182 0.75 LMNA (0.56) SMN1; SMN2KMT2AALDH1A1HTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8673910-B2 Proteasome inhibitors for selectively inducing apoptosis in cancer cells H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) 2014-03-18 US disclosed
US-8673910-B2 Proteasome inhibitors for selectively inducing apoptosis in cancer cells H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) 2014-03-18 US disclosed
US-8673910-B2 Proteasome inhibitors for selectively inducing apoptosis in cancer cells H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) 2014-03-18 US disclosed
US-20110201609-A1 PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) 2011-08-18 US disclosed
US-20110201609-A1 PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) 2011-08-18 US disclosed
US-20110201609-A1 PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) 2011-08-18 US disclosed
WO-2010005534-A2 PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2010-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201609-A1 PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS PSMB7, PSMD7, PSMB6 AKT1 2024/4885SMN1; SMN2 2696/4885KMT2A 2094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.